AssetMark Inc’s Praxis Precision Medicines PRAX Stock Holding History

AssetMark Inc’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7	Closed	-$539	–	2736
2024 Q4	$539	Buy	+7	New	+$506	﹤0.01%	2360

Other funds holding PRAX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AssetMark Inc's PRAX Position: Q1 2025 in Review

AssetMark Inc sold out of Praxis Precision Medicines (PRAX) in Q1 2025, closing a stake of 7 shares — an estimated $539 sold.

AssetMark Inc first reported a position in PRAX in Q4 2024 and held it in 1 quarter. The position peaked at $539 in Q4 2024. 150 funds tracked by Wall St. Rank hold PRAX as of Q1 2025.

AssetMark Inc reported no remaining Praxis Precision Medicines position as of Q1 2025 after selling out during the quarter.
AssetMark Inc sold 7 Praxis Precision Medicines shares in Q1 2025, an estimated $539.
AssetMark Inc first reported a position in Praxis Precision Medicines in Q4 2024 and held it in 1 quarter.
AssetMark Inc's Praxis Precision Medicines position peaked at $539 in Q4 2024.
150 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2025.

Based on AssetMark Inc's 13F filing for Q1 2025, filed 6 May 2025.